News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,566 Results
Type
Article (14898)
Company Profile (299)
Press Release (266363)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79834)
Career Advice (162)
Deals (13337)
Drug Delivery (39)
Drug Development (50697)
Employer Resources (31)
FDA (5838)
Job Trends (5167)
News (145075)
Policy (10072)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21761)
ALS (124)
Alzheimer's disease (1030)
Antibody-drug conjugate (ADC) (241)
Approvals (6031)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (343)
Cancer (3127)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43664)
Collaboration (1148)
Company closure (2)
Compensation (591)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4316)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1378)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (213)
Earnings (31642)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51657)
Executive appointments (621)
FDA (7585)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (486)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1204)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7345)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (419)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (130)
Medical device (2662)
Medtech (2671)
Mergers & acquisitions (6615)
Metabolic disorders (724)
Multiple sclerosis (102)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1949)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (126)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (327)
Peanut (43)
People (26649)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15473)
Phase 2 (20285)
Phase 3 (12820)
Pipeline (3239)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (648)
Real estate (1447)
Recruiting (12)
Regulatory (9894)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (10)
Last 7 days (344)
Last 30 days (1357)
Last 365 days (17831)
2026 (1651)
2025 (18098)
2024 (20547)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18250)
Australia (3110)
California (7076)
Canada (1836)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39155)
Florida (902)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5578)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1645)
New Mexico (13)
New York (1761)
North Carolina (825)
North Dakota (6)
Northern California (3473)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2806)
Tennessee (40)
Texas (904)
United States (23322)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,566 Results for "cymabay therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics.
February 12, 2024
·
11 min read
Biotech Bay
CymaBay Therapeutics to Participate in Upcoming Investment Conferences
CymaBay Therapeutics, Inc. today announced that members of its management team will participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference, February 7-8, in New York, NY.
January 31, 2024
·
1 min read
Biotech Bay
CymaBay Therapeutics to Present at Upcoming Investment Conferences
CymaBay Therapeutics, Inc. today announced that members of its management team will participate in the UBS Biopharma Conference, November 8-9th in Miami Beach, FL.
November 6, 2023
·
1 min read
Deals
Gilead Sciences Announces Completion of Acquisition of CymaBay
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value.
March 22, 2024
·
6 min read
Biotech Bay
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 20, 2024
CymaBay Therapeutics, Inc. announced the grant of inducement awards to three employees on February 16, 2024 in connection with the employees’ commencement of employment at CymaBay.
February 20, 2024
·
2 min read
Biotech Bay
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that its President and Chief Executive Officer, Sujal Shah, will present at the upcoming 42nd Annual JP Morgan Healthcare Conference taking place January 8 -11 in San Francisco, California.
January 2, 2024
·
1 min read
Biotech Bay
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 18, 2023
CymaBay Therapeutics, Inc. announced the grant of inducement awards to four employees on December 15, 2023 in connection with the employees’ commencement of employment at CymaBay.
December 18, 2023
·
2 min read
Biotech Bay
CymaBay Therapeutics to Present at the Cantor Global Healthcare Conference
CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that members of its management team will participate in the Cantor Global Healthcare Conference, September 26-28th at the InterContinental Barclay Hotel in New York.
September 15, 2023
·
1 min read
Drug Development
CymaBay’s Liver Disease Candidate Hits Phase III Primary, Secondary Endpoints
Analysts said CymaBay’s seladelpar is emerging as the “therapy of choice in the second-line setting” and “could impact the treatment landscape” across a spectrum of primary biliary cholangitis patients.
September 7, 2023
·
2 min read
·
Connor Lynch
Biotech Bay
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 16, 2024
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced the grant of inducement awards to two employees on January 12, 2024 in connection with the employees’ commencement of employment at CymaBay.
January 16, 2024
·
2 min read
1 of 28,157
Next
